A novel target in aged fracture healing
老年骨折愈合的新目标
基本信息
- 批准号:10798768
- 负责人:
- 金额:$ 41.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-30 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgeAgingAntibodiesApolipoprotein EBiologyBone MarrowBone RegenerationBone TissueBone callusCell Culture TechniquesCell Surface ReceptorsCell surfaceCirculationClinicDataDepositionDoseElderlyFractureHealthHealthcareHepatocyteHumanImmunoglobulin GImpairmentIn VitroInjuryInterventionLigandsLiteratureLiverLoxP-flanked alleleMUSK geneMalignant neoplasm of liverMechanicsModelingMorbidity - disease rateMusNeuromuscular JunctionOperative Surgical ProceduresOrthopedicsOsteoblastsOutcomePathway interactionsPatientsPhenotypePhosphorylationPopulationProteinsPublic HealthPublishingReceptor Protein-Tyrosine KinasesRegimenReportingRoleSignal PathwaySignal TransductionSmall Interfering RNAStromal CellsTestingTherapeuticTimeTissuesTranscriptTransgenic MiceTranslatingTreatment ProtocolsWorkagedbonebone agingbone fracture repairbone healingbone repaircare burdenclinical translationcohortcostimprovedinducible Creinhibitorknock-downmalemineralizationmortalitymouse Cre recombinasemouse modelneutralizing antibodynoveloptimal treatmentsosteoblast differentiationosteogenicpre-clinicalpreventprogenitorprotein expressionreceptorsingle-cell RNA sequencingtherapeutic targettherapy developmenttissue culture
项目摘要
ABSTRACT
Bone fractures occur in 50% of the population causing significant morbidity and mortality and costing more than
$20 billion annually. Advanced age diminishes bone repair capacity and is associated with increased surgical
intervention at the time of the injury and subsequently with the need for revisions. The development of therapies
aimed at enhancing bone repair would significantly reduce the burden on the geriatric population. We recently
identified Apolipoprotein E (ApoE) to be an age-associated inhibitor of fracture repair. ApoE is a circulatory
protein and increases in abundance with age in mice and in humans. In our published work, circulating ApoE
inhibited osteoblast differentiation and activity decreasing the amount of bone deposited within the fracture
callus. The liver produces >90% of the ApoE found in circulation, as such, we delivered siRNA against ApoE
using an AAV targeting hepatocytes in aged mice. Circulating levels of ApoE were dramatically decreased and
subsequent aged bone healing was greatly improved. This finding serves as a ‘proof of concept’ that ApoE is a
viable target to improve aged fracture repair. Within this proposal we will build on these findings identifying
interventions that can be translated to clinic to improve aged bone healing. In Aim 1 we will determine whether
neutralizing circulating ApoE improves aged fracture healing. We have developed an ApoE-neutralizing antibody.
A small cohort of aged male mice underwent fracture injury and were later treated with this antibody IP. Versus
IgG-treated mice, the calluses of anti-ApoE treated mice contained higher amounts of bone tissue. In this aim
we will identify the optimal regimen and dose of antibody to use and determine how this treatment changes the
stages of fracture repair. Furthermore, we have identified ApoE-based inhibition to propagate through
osteoblastic muscle-specific kinase (MuSK), a cell-surface tyrosine kinase receptor whose osteogenic
expression and function has yet to be reported in the literature. In Aim 2 we will we will use MuSK floxed mice
crossed with inducible Cre-recombinase mice to identify the role of osteogenic progenitor and osteoblastic MuSK
in bone repair. In Aim 3 we will identify the mechanism by which ApoE decreases osteoblast differentiation.
Using in vitro cell culture techniques, we have identified the Yap/Taz pathway to be modulated with ApoE
treatment. An osteoblastic cell-surface receptor for this pathway has yet to be identified. We have determined
MuSK to potentially serve as such a receptor. Using transgenic mouse models, we will determine functionality
of MuSK in osteoblast biology and investigate the role of MuSK in ApoE-based osteoblast inhibition/signal
transduction.
摘要
骨折发生在50%的人口中,导致显著的发病率和死亡率,
每年200亿美元。高龄会降低骨修复能力,并与手术次数增加有关。
在受伤时进行干预,随后需要进行翻修。治疗方法的发展
旨在增强骨修复的治疗将显著减轻老年人群的负担。我们最近
确定载脂蛋白E(ApoE)是一种与年龄相关的骨折修复抑制剂。ApoE是一种循环系统
在小鼠和人类中,蛋白质的丰度随着年龄的增长而增加。在我们发表的工作中,循环ApoE
抑制成骨细胞分化和活性,减少骨折内沉积的骨量
愈伤组织肝脏产生循环中发现的> 90%的ApoE,因此,我们递送了针对ApoE的siRNA。
使用靶向老年小鼠肝细胞的AAV。ApoE的循环水平显著降低,
随后的老化骨愈合大大改善。这一发现可以作为ApoE是一种“概念证明”。
改善老年骨折修复的可行目标。在本提案中,我们将以这些调查结果为基础,
可以转化为临床干预,以改善老年骨愈合。在目标1中,我们将确定
中和循环ApoE改善老化骨折愈合。我们研制出了一种ApoE中和抗体。
一小群老年雄性小鼠经历骨折损伤,随后用该抗体IP治疗。与
IgG处理的小鼠中,抗ApoE处理的小鼠的愈伤组织含有更高量的骨组织。在这一目标中,
我们将确定最佳方案和抗体剂量,并确定这种治疗如何改变
骨折修复的阶段。此外,我们已经确定了基于ApoE的抑制通过
成骨细胞肌肉特异性激酶(MuSK),一种细胞表面酪氨酸激酶受体,其成骨细胞特异性激酶(MSK)是一种细胞表面酪氨酸激酶受体,
表达和功能尚未在文献中报道。在目标2中,我们将使用MuSK floxed小鼠
与诱导型Cre重组酶小鼠杂交,以确定成骨祖细胞和成骨细胞MuSK的作用
在骨修复中。在目标3中,我们将确定ApoE降低成骨细胞分化的机制。
使用体外细胞培养技术,我们已经鉴定了ApoE调节的雅普/Taz通路
治疗该通路的成骨细胞表面受体尚未确定。我们已经确定
MuSK可能作为这样的受体。使用转基因小鼠模型,我们将确定功能
MuSK在成骨细胞生物学中的作用,并研究MuSK在基于ApoE的成骨细胞抑制/信号传导中的作用。
转导
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gurpreet Baht其他文献
Gurpreet Baht的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gurpreet Baht', 18)}}的其他基金
Correction of Immune Response Improves Aged Fracture Healing
纠正免疫反应可改善老化骨折的愈合
- 批准号:
10266845 - 财政年份:2020
- 资助金额:
$ 41.6万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 41.6万 - 项目类别:
Operating Grants